Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Melanoma
  • Programmed Cell Death 1 Receptor
  • Skin Neoplasms

abstract

  • In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects. (Funded by Merck Sharp and Dohme; ClinicalTrials.gov number, NCT01295827.).

publication date

  • July 23, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4126516

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1305133

PubMed ID

  • 23724846

Additional Document Info

start page

  • 134

end page

  • 44

volume

  • 369

number

  • 2